Dr. W. Kyle Simmons is Professor of Pharmacology and Physiology at the Oklahoma State University Center for Health Sciences and Director of the OSU Biomedical Imaging Center. For nearly two decades, his research has leveraged advanced neuroimaging, psychophysiology, and endocrine, metabolic, and immune biomarkers to elucidate the biological determinants of health-related behaviors across healthy and clinical populations, with particular emphasis on mood disorders, obesity, eating disorders, and substance use disorders. Following foundational work on the neural bases of appetite and interoception during his training at Emory University, the NIMH Intramural Research Program, and the Laureate Institute for Brain Research, Dr. Simmons moved to industry to lead Janssen Research & Development's mood disorders biomarker program.  Since moving to OSU in 2020 to help develop the Hardesty Center for Clinical Research and Neuroscience, his work has centered on evaluating incretin-based therapeutics as novel treatments for addiction and obesity. He currently leads the Semaglutide Therapy for Alcohol Reduction (STAR) Study, a phase II double-blind, placebo-controlled randomized clinical trial for alcohol use disorder, and serves as site principal investigator for multiple industry-sponsored trials testing GLP-1 receptor agonists for substance use disorders. The work of Dr. Simmons and his research colleagues has garnered national and international media attention in such news outlets at CBS News, NBC News, The Washington Post, The New York Times and The Atlantic.